Exenatide(ex enn’ ah tyde)
Bydureon, Byetta
PREGNANCY CATEGORY C
Drug Classes
Antidiabetic
Incretin mimetic drug
Therapeutic Actions
An incretin that mimics the enhancement of glucose-dependent insulin secretion by pancreatic beta cells, depresses inappropriately elevated glucagon secretion, and slows gastric emptying, leading to lower blood glucose levels. Also associated with appetite suppression and weight loss.
Indications
Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes
Add-on therapy with insulin glargine, with or without metformin, with diet and exercise to help improve glycemic control in adults with type 2 diabetes
Contraindications and Cautions
Contraindicated with hypersensitivity to exenatide or any of its components, end stage renal disease, severe GI disease, type 1 diabetes, diabetic ketoacidosis, lactation, history of pancreatitis.
Use cautiously with pregnancy.
Available Forms
Solution for injection, solution in a prefilled pen—250 mcg/mL as 5 mcg/dose or 10 mcg/dose; extended-release injectable suspension—2 mg
Dosages
Adults
5 mcg by subcutaneous injection bid at any time within 60 min before the morning and evening meals or the two main meals of the day, approximately 6 hr apart. May be increased to 10 mcg bid after 1 month of therapy, if needed. May be given in combination with oral antidiabetic drugs. ER form: 2 mg by subcutaneous injection once every 7 days.
Patients with renal impairment
For CrCl of 30–50 mL/min, use caution when increasing dosage from 5 to 10 mcg. For CrCl of less than 30 mL/min, use not recommended.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
